Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

25.81
+0.60002.38%
Post-market: 25.840.0300+0.12%18:02 EDT
Volume:1.87M
Turnover:47.87M
Market Cap:2.54B
PE:-4.43
High:25.85
Open:25.22
Low:25.11
Close:25.21
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.92
T/O Rate:2.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-8.72
PE(LYR):-4.43

Loading ...

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Reuters
·
Aug 05

Ultragenyx Pharmaceutical Q2 EPS $(0.90) Beats $(1.51) Estimate, Sales $214.000M Beat $158.777M Estimate

Benzinga Earnings
·
Aug 05

Ultragenyx Q2 EPS USD -0.9

Reuters
·
Aug 05

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

GlobeNewswire
·
Aug 05

Ultragenyx EVP, Chief Legal Officer Karah Parschauer Disposes of 1,900 Common Shares for $47,348‬

Reuters
·
Aug 05

Ultragenyx Pharma is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 04

Ultragenyx price target lowered to $35 from $43 at Guggenheim

TIPRANKS
·
Aug 04

Ultragenyx Grants 65,886 Restricted Stock Units to 39 New Hires Under Inducement Plan

Reuters
·
Jul 25

Ultragenyx Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 25

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 25

Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Jul 22

Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024

Dow Jones
·
Jul 18

Wedbush Releases a Hold Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Jul 13

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating

MT Newswires Live
·
Jul 13

Ultragenyx Releases 2025 Impact Report Outlining ESG Progress Across Six Pillars

Reuters
·
Jul 08

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors

THOMSON REUTERS
·
Jun 23

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

GlobeNewswire
·
Jun 23

Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs

Reuters
·
Jun 22

Ultragenyx grants 44,409 RSUs to 15 new hires under inducement plan

Reuters
·
Jun 20